Please try another search
Bukwang Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was KRW 36,915.36 million compared to KRW 43,420.1 million a year ago. Net loss was KRW 2,732.1 million compared to net income of KRW 483.01 million a year ago. Basic loss per share from continuing operations was KRW 40 compared to basic earnings per share from continuing operations of KRW 7 a year ago. Basic loss per share was KRW 40 compared to basic earnings per share of KRW 7 a year ago.For the six months, sales was KRW 0.00001 million compared to KRW 0.00022 million a year ago. Net loss was KRW 4,643.58 million compared to KRW 4,421.77 million a year ago. Basic loss per share from continuing operations was KRW 68 compared to KRW 65 a year ago. Basic loss per share was KRW 68 compared to KRW 65 a year ago.
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Total Revenue | 36915.36 | 34393.44 | 25020.92 | 20252.9 |
Gross Profit | 17037.77 | 15537.8 | 6527.72 | 6218.21 |
Operating Income | -1886.04 | -1628.3 | -15712.04 | -16203.42 |
Net Income | -2732.1 | -1911.48 | -10796.86 | -16111.03 |
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Total Assets | 349195.34 | 422512.9 | 429017.05 | 394279.58 |
Total Liabilities | 119932.7 | 189939.55 | 194752.38 | 144295.93 |
Total Equity | 229262.64 | 232573.35 | 234264.67 | 249983.65 |
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 1021.05 | 12745.38 | 17614.43 | -9640.55 |
Cash From Investing Activities | 10860.73 | -946.15 | 5707.83 | -6547.48 |
Cash From Financing Activities | -64362.27 | -1135.55 | 47510.3 | 29704.28 |
Net Change in Cash | -53252.42 | 11232.25 | 69918.23 | 13009.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review